Compare Chandra Daya Investasi Tbk. (CDIA) vs Tempo Scan Pacific Tbk. (TSPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chandra Daya Investasi Tbk. vs Tempo Scan Pacific Tbk. — how do they compare? Chandra Daya Investasi Tbk. trades at Rp635 (market cap 79.27T, 22.37M 24h volume), while Tempo Scan Pacific Tbk. trades at Rp2,520 (market cap 11.18T, 613K 24h volume). The key difference: Chandra Daya Investasi Tbk. is far larger — about 7.1× Tempo Scan Pacific Tbk.'s market cap, and Chandra Daya Investasi Tbk. is more actively traded (22.37M versus 613K). Which is the better fit depends on your goals.
| CDIA | TSPC | |
|---|---|---|
Market Cap | 79.27T | 11.18T |
Volume | 22.37M | 613K |
Lot | 223.74K | 6.13K |
Turnover | 14.26B | 1.54B |
Average Price | 637.18 | 2,511.52 |
Value | 14.26B | 1.54B |
Indicative Equilibrium Price | 635 | 2,520 |
Indicative Equilibrium Volume | 3.37K | 17 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chandra Daya Investasi Tbk.
PT Chandra Daya Investasi Tbk. the (Company) was established based on Notarial Deed No. 26 dated February 8, 2023, of Jose Dirma Satria, S.H., M.Kn., Notary in Jakarta. The Company started its commercial operations in 2023. The Company is a subsidiary of PT Chandra Asri Pacific Tbk and belongs to a group of companies owned by PT Barito Pacific Tbk (Barito Pacific Group). Mr. Pajogo Pangestu is the ultimate beneficial owner of the Company.
Read more on CDIA →About Tempo Scan Pacific Tbk.
PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.
Read more on TSPC →
